Download Full Text (1.8 MB)

Document Type



Migraine headaches are one of the most common causes of primary headaches and one of the leading causes of disability worldwide. While the mechanism of migraines are not entirely understood, they can result in significant disability (DynaMed, 2023). Dihydroergotamine was introduced for migraine treatment in the 1920s and in the 1990s triptans were introduced and have been the mainstay of acute migraine treatment since their introduction (Solomon et al., 2008). In recent years, there have been several developments in the acute treatment and prophylaxis of migraine headaches. CGRP receptor antagonists and 5-HT1F receptor agonists have been researched, developed, and approved by the FDA for acute migraine treatment. The purpose of this literature review was to compare the efficacy and safety of rimegepant, a CGRP receptor antagonist and lasmiditan, a 5HT1F receptor antagonist in the treatment of acute migraine attacks. This comparison was accomplished by a thorough review of scientific articles available through various resources such as PubMed, Clinical Key and CINAHL Complete. The results from 12 clinic trials that were reviewed indicated that rimegepant and lasmiditan are both superior to placebo in aborting an acute migraine in addition to eliminating most bothersome associated symptoms. Rimegepant and lasmiditan were also proved to be safe in the tested populations although each pharmacological intervention does carry its own set of potential side effects. There have been no direct studies comparing both drugs or comparing the drugs to triptans, however several meta-analyses showed triptans to still be superior in aborting acute migraine headaches


Physician Assistant Studies

Degree Name

Master of Physician Assistant Studies (MPAS)

First Advisor

Metzger, Jay

Publication Date

Spring 2023


migraine disorders/drug therapy, double-blind method, calcitonin gene related peptide receptor antagonists/therapeutic use, 5-HT1F receptor agonists adult, oral administration, lasmiditan, rimegepant, safety, and triptan


Medicine and Health Sciences

Evaluating and comparing the safety and efficacy of rimegepant versus lasmiditan in aborting acute migraine headaches in the adult migraineur